October 11, 2017 / 8:42 PM / 2 months ago

BRIEF-AFT Pharmaceuticals ‍announces positive results for Maxigesic IV​ phase 3 trial

Oct 12 (Reuters) - AFT Pharmaceuticals Ltd

* ‍Announced results of phase 3 clinical trial for maxigesic iv​

* Study was conducted at a cost of nz$7.5 million; study was successful and met primary endpoint​

* Results indicate statistically significant difference between treatment groups in primary endpoint Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below